Major obesity therapies in development include retatrutide (triple agonist), CagriSema (GLP-1/amylin), survodutide (GLP-1/glucagon), orforglipron (oral GLP-1), the amylin analogues cagrilintide and petrelintide, next-generation GIP agents, and muscle-preserving drugs such as bimagrumab. All are investigational. Oral semaglutide 25 mg has already graduated to approval.
Structured companion to the flagship future chapter. Section accent: family --teal.
[verify]. Status re-verified on update.Graduated to approved
✅ Oral semaglutide 25 mg — GRADUATED (no longer pipeline)
What is it. A high-dose oral formulation of semaglutide for chronic weight management.
Mechanism. GLP-1 receptor agonist (oral peptide with specific food/water dosing conditions).
Current phase. 🟢 Established — FDA-approved (December 2025) as the first oral GLP-1 for obesity. It has left this database; full details live on its drug page. → Semaglutide (/treat/glp1/semaglutide)
Why it's listed here. So the database stays honest about what has crossed the line from investigational to approved — the model for what the agents below are trying to achieve.
The emerging agents
1. Retatrutide 🟠 Limited (phase 3 ongoing)
| Field | Detail |
|---|---|
| What is it | An investigational once-weekly injectable for obesity and type 2 diabetes |
| Mechanism | GLP-1 / GIP / glucagon triple agonist — adds a glucagon arm (possible ↑ energy expenditure) to incretin appetite effects |
| Current phase | Phase 3 (TRIUMPH program) — not FDA-approved |
| Human evidence | Phase 3 TRIUMPH-1: up to ~30.3% mean total weight loss at the highest dose [verify — topline]; a trial average, not a personal result |
| Potential | Largest incretin-era weight loss to date; possible added liver/metabolic benefit from glucagon agonism |
| Risks | Glucagon effects on glucose, heart rate and the liver; GI tolerability; long-term safety of triple agonism |
| Unknowns | Durability, muscle/body-composition effects, cardiovascular outcomes, real-world tolerability |
| Likely clinical role | If approved, a high-efficacy option for loss beyond dual agonists — pending safety confirmation |
Phase badge: 🟠 Limited / investigational.
2. CagriSema 🟠 Limited
| Field | Detail |
|---|---|
| What is it | An investigational fixed combination injectable for obesity |
| Mechanism | Cagrilintide (long-acting amylin analogue) + semaglutide (GLP-1) — complementary appetite pathways |
| Current phase | Phase 3 (REDEFINE program) — not FDA-approved |
| Human evidence | REDEFINE 1: ~22.7% mean total weight loss [verify]. REDEFINE 4: ~23%, but missed non-inferiority versus tirzepatide in the head-to-head |
| Potential | High efficacy; validates amylin as a partner mechanism; possible favourable body composition (unproven) |
| Risks | GI tolerability; added complexity/cost of a combination |
| Unknowns | Whether adding amylin truly beats the best single dual agonist (REDEFINE 4 says not clearly); durability; muscle effects |
| Likely clinical role | A strong option if approved — but not an automatic upgrade over tirzepatide on current data |
Phase badge: 🟠 Limited / investigational.
3. Survodutide 🔴 Experimental
| Field | Detail |
|---|---|
| What is it | An investigational injectable for obesity and MASH |
| Mechanism | GLP-1 / glucagon dual agonist — glucagon arm of particular interest for the liver |
| Current phase | Investigational — not approved for obesity or MASH |
| Human evidence | Reported improvement in MASH endpoints in earlier-phase work — qualitative; [verify] figures. → GLP-1 & Fatty Liver |
| Potential | Treats obesity and MASH together via a distinct mechanism |
| Risks | Glucagon effects on glucose and heart rate; GI tolerability |
| Unknowns | Weight efficacy versus approved drugs; confirmatory MASH and safety data |
| Likely clinical role | Possible future option where MASH + obesity is the driver — if trials confirm |
Phase badge: 🔴 Experimental.
4. Orforglipron 🟠 Limited
| Field | Detail |
|---|---|
| What is it | An investigational oral drug for obesity and type 2 diabetes |
| Mechanism | Non-peptide, small-molecule oral GLP-1 agonist (no strict peptide food/water dosing rules) |
| Current phase | Phase 3 data reported — investigational, not approved |
| Human evidence | Phase 3 results in obesity and diabetes; state efficacy qualitatively — [verify] figures |
| Potential | A scalable oral option that could widen access beyond injectables |
| Risks | GI tolerability; long-term safety being defined |
| Unknowns | Efficacy relative to injectable incretins; durability; approval timing |
| Likely clinical role | If approved, a convenient oral first-line option — distinct from oral semaglutide (a peptide) |
Phase badge: 🟠 Limited / investigational.
5. Cagrilintide 🔴 Experimental (standalone)
| Field | Detail |
|---|---|
| What is it | A long-acting amylin analogue, studied alone and as the amylin half of CagriSema |
| Mechanism | Amylin receptor agonist — appetite suppression through a non-incretin pathway |
| Current phase | Investigational as monotherapy — not approved |
| Human evidence | Most mature evidence is within CagriSema (see entry 2); standalone data are earlier — qualitative, [verify] |
| Potential | A different mechanism/side-effect profile; a partner for combinations |
| Risks | GI tolerability; standalone efficacy uncertain versus incretins |
| Unknowns | Monotherapy effect size; whether amylin preserves lean mass (hypothesis, not fact) |
| Likely clinical role | Most plausibly a combination partner rather than a standalone drug |
Phase badge: 🔴 Experimental.
6. Petrelintide 🔴 Experimental
| Field | Detail |
|---|---|
| What is it | A long-acting amylin analogue in development as monotherapy and in combinations |
| Mechanism | Amylin receptor agonist (non-incretin appetite pathway) |
| Current phase | Early clinical — investigational, not approved |
| Human evidence | Early-phase data; efficacy and profile still being defined — qualitative, [verify] |
| Potential | A cleaner-tolerability or lean-mass-sparing amylin option (unproven) |
| Risks | Unknown long-term safety; GI effects |
| Unknowns | Standalone efficacy; comparison with incretins and with cagrilintide |
| Likely clinical role | Possible future monotherapy or combination amylin agent — early days |
Phase badge: 🔴 Experimental.
7. Next-generation GIP agents 🔴 Experimental
| Field | Detail |
|---|---|
| What is it | A research class exploring GIP-receptor targeting beyond current dual agonism |
| Mechanism | GIP-directed — notably, both GIP agonism and, paradoxically, antagonism show metabolic effects, so the biology is genuinely unsettled |
| Current phase | Preclinical to early clinical — investigational |
| Human evidence | Limited standalone human data; most GIP evidence to date comes bundled in tirzepatide. → Tirzepatide |
| Potential | Fine-tuning the GIP arm for efficacy, tolerability or body composition |
| Risks | Uncertain — the mechanism itself is not fully resolved |
| Unknowns | Whether agonism or antagonism is the better strategy; standalone value |
| Likely clinical role | A direction, not a named product — most useful as a combination component |
Phase badge: 🔴 Experimental.
8. Bimagrumab / activin-pathway (muscle-preserving) agents 🔴 Experimental
| Field | Detail |
|---|---|
| What is it | Agents aimed at preserving or building muscle while fat is lost, alone or with a GLP-1 |
| Mechanism | Activin/myostatin-pathway blockade to shift loss toward fat and protect fat-free mass |
| Current phase | Investigational — not approved for this use |
| Human evidence | Early data suggest more fat loss with relatively more lean-mass preservation — qualitative, [verify] |
| Potential | Keeps loss "fat-specific"; protects function, especially in older/frailer patients. → GLP-1 & Muscle Loss |
| Risks | Long-term safety unknown; other activin-pathway effects |
| Unknowns | Whether measured lean mass preserved = real strength/function preserved (not the same thing) |
| Likely clinical role | A future add-on to incretin therapy to protect muscle — unproven as yet |
Phase badge: 🔴 Experimental.
9. Precision obesity / pharmacogenomics 🔴 Experimental
| Field | Detail |
|---|---|
| What is it | Matching the drug to the person using genetics, hormones, behaviour or metabolic subtype |
| Mechanism | Biomarker- or genotype-guided treatment selection (not a drug itself) |
| Current phase | 🔴 Experimental for common obesity; established only in rare monogenic disease |
| Human evidence | Heritability ~40–70%; setmelanotide works for defined monogenic obesity (POMC, LEPR, Bardet-Biedl). No validated drug-response test for common obesity. → Genetics of Obesity |
| Potential | Companion tests guiding first-line choice; less trial-and-error |
| Risks | Premature commercial "obesity gene tests"; equity/access; over-claiming |
| Unknowns | Whether polygenic scores add real predictive value in practice |
| Likely clinical role | Long-term direction; today, only monogenic targeting is clinical |
Phase badge: 🔴 Experimental (common obesity) / 🟢 Established (rare monogenic, via setmelanotide).
Reading the database at a glance
| Agent | Mechanism | Phase badge | One-line status |
|---|---|---|---|
| Oral semaglutide 25 mg | GLP-1 (oral) | 🟢 Established | Approved Dec 2025 — graduated → Semaglutide |
| Retatrutide | GLP-1/GIP/glucagon | 🟠 Limited | Phase 3; up to ~30.3% mean; not approved |
| CagriSema | GLP-1/amylin | 🟠 Limited | ~22.7% (REDEFINE 1); missed non-inferiority vs tirzepatide (REDEFINE 4) |
| Survodutide | GLP-1/glucagon | 🔴 Experimental | Obesity + MASH; not approved |
| Orforglipron | Oral GLP-1 (small molecule) | 🟠 Limited | Phase 3; investigational |
| Cagrilintide | Amylin analogue | 🔴 Experimental | Standalone investigational; partner in CagriSema |
| Petrelintide | Amylin analogue | 🔴 Experimental | Early clinical |
| Next-gen GIP | GIP-directed | 🔴 Experimental | Direction, not a product |
| Bimagrumab / activin | Muscle-preserving | 🔴 Experimental | Preserve muscle while losing fat; unproven |
| Precision obesity | Genotype/biomarker matching | 🔴 Experimental | Clinical only in rare monogenic disease |
SIGNATURE — "What the evidence says: the emerging pipeline"
- What we know: One agent has crossed to approval (oral semaglutide 25 mg). The rest are investigational, with the strongest late-stage efficacy signals from retatrutide and CagriSema.
- What we think: Triple agonism and amylin combinations will likely lift efficacy; oral small molecules will widen access; muscle-preservation and precision approaches will shape quality of treatment.
- What we don't know: Long-term safety and outcomes; whether combinations reliably beat the best single agent (REDEFINE 4 cautions against assuming so); whether precision matching works for common obesity.
- What patients should do: Judge each agent by its phase badge, use approved options now, and treat any "coming soon" claim as unverified until it isn't.
Questions patients ask
What obesity drugs are in development right now?
Retatrutide, CagriSema, survodutide, orforglipron, the amylin analogues cagrilintide and petrelintide, next-gen GIP agents and muscle-preserving drugs — all investigational. Oral semaglutide 25 mg is already approved. Grade 🟠 Limited (pipeline) → The Next Generation of Obesity Medicine
Which emerging drug causes the most weight loss?
Retatrutide has reported the highest figure — up to ~30.3% mean in phase 3 — but it is investigational, and a trial average is not a personal result. Grade 🟠 Limited
Is CagriSema better than the drugs I can get now?
Not clearly — it reached ~22.7% in REDEFINE 1 but missed non-inferiority versus tirzepatide in REDEFINE 4. Novelty didn't beat the best approved dual agonist. Grade 🟠 Limited
What's the difference between orforglipron and oral semaglutide?
Oral semaglutide is an approved oral peptide with strict food/water dosing rules; orforglipron is an investigational non-peptide small molecule that may be simpler to take. Grade A 🟢 (sema) / 🟠 (orforglipron) → Semaglutide
Are amylin drugs safer for muscle?
It's a hypothesis, not an established fact. Amylin agents and activin-pathway drugs (bimagrumab) are being studied for body composition, but "lean mass" on a scan isn't the same as strength. Grade 🔴 Experimental → GLP-1 & Muscle Loss
Can my genes tell me which of these will work best?
Only in rare monogenic obesity (setmelanotide for POMC/LEPR/Bardet-Biedl). For common obesity there's no validated drug-response test yet. Grade 🔴 Experimental → Genetics of Obesity
When will these be approved and available?
That depends on ongoing trials and regulatory review, which we can't predict — we re-verify status each update. Only oral semaglutide 25 mg is approved so far. Grade 🟠 Limited
KEEP READING
- The Next Generation of Obesity Medicine — the narrative flagship this database supports.
- The 10 Most Important New Developments — how these agents fit the bigger picture.
- Semaglutide — where oral semaglutide 25 mg now lives, having graduated.
- Tirzepatide — the benchmark the pipeline is compared against.
- GLP-1 & Fatty Liver — the liver angle behind survodutide.
- Genetics of Obesity — the basis for precision and gene-directed therapy.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: TRIUMPH (retatrutide); REDEFINE 1/4 (CagriSema); FDA approval of oral semaglutide 25 mg (Dec 2025); survodutide, orforglipron, cagrilintide, petrelintide, bimagrumab and next-gen GIP development programs; setmelanotide labeling. All investigational agents re-verified on update. Educational only; pipeline agents are not available treatments and this is not individualized advice.
